Holen Sie sich die Stockscreener-App
81.05
0.26%
-0.21
Handel nachbörslich:
81.05
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt EW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$81.26
Offen:
$81.14
24-Stunden-Volumen:
3.30M
Relative Volume:
0.75
Marktkapitalisierung:
$46.73B
Einnahmen:
$6.07B
Nettoeinkommen (Verlust:
$1.06B
KGV:
44.87
EPS:
1.8063
Netto-Cashflow:
$1.34B
1W Leistung:
-1.28%
1M Leistung:
-7.03%
6M Leistung:
+5.74%
1J Leistung:
+12.49%
1-Tages-Spanne:
$79.40
$81.72
1-Wochen-Bereich:
$77.60
$82.17
52-Wochen-Spanne:
$65.94
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Firmenname
Edwards Lifesciences Corp
Sektor
Branche
Telefon
(949) 250-2500
Adresse
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
ABT
Abbott Laboratories
|
102.87 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-12-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2025-10-29 | Hochstufung | Jefferies | Hold → Buy |
| 2025-10-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-10-07 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-07-29 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-04-24 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Stifel | Hold → Buy |
| 2025-01-16 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-12-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-11 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-09-18 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-31 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-07-29 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-07-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-07-25 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-25 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-25 | Herabstufung | Truist | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-14 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-03-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-02-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-04 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-28 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2023-09-26 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-03-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-02-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-31 | Herabstufung | Bernstein | Outperform → Underperform |
| 2023-01-30 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-12-06 | Herabstufung | Stifel | Buy → Hold |
| 2022-10-28 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-10-26 | Eingeleitet | Mizuho | Buy |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-29 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-03-16 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Hochstufung | UBS | Neutral → Buy |
| 2022-01-27 | Bestätigt | Citigroup | Buy |
| 2022-01-27 | Bestätigt | Evercore ISI | Outperform |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Buy |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2021-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-12-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-07-30 | Bestätigt | Canaccord Genuity | Buy |
| 2021-07-30 | Bestätigt | Deutsche Bank | Hold |
| 2021-07-30 | Bestätigt | Jefferies | Buy |
| 2021-07-30 | Bestätigt | Morgan Stanley | Overweight |
| 2021-07-30 | Bestätigt | Oppenheimer | Outperform |
| 2021-07-30 | Bestätigt | Stifel | Buy |
| 2021-07-30 | Bestätigt | UBS | Neutral |
| 2021-07-30 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-04-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-11 | Bestätigt | Canaccord Genuity | Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Underperform |
| 2020-04-28 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Outperform |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-10-24 | Bestätigt | Canaccord Genuity | Buy |
| 2019-09-23 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-24 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-18 | Bestätigt | Canaccord Genuity | Buy |
| 2019-01-18 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Deutsche Bank | Hold |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-10-02 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-10-02 | Herabstufung | Guggenheim | Buy → Neutral |
Alle ansehen
Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten
Donald Bobo Jr Sells 22,680 Shares of Edwards Lifesciences (NYSE:EW) Stock - MarketBeat
Edwards Lifesciences (EW) VP sells 22,680 shares after option exercise - Stock Titan
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
EW PE Ratio & Valuation, Is EW Overvalued - Intellectia AI
Edwards Lifesciences Corporation $EW Shares Acquired by J. Safra Sarasin Holding AG - MarketBeat
Assessing Edwards Lifesciences (EW) Valuation As Growth Hopes Contrast With Rich P/E Multiple - Yahoo Finance
Two Year Data on Edwards Lifesciences’ EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits - BioSpace
Edwards Lifesciences Hits Day Low of $78.58 Amid Price Pressure - Markets Mojo
Edwards Lifesciences Corp (EW) Shares Gap Down to $79.34 on Mar 30 - GuruFocus
Edwards Lifesciences Announces New Data on EVOQUE Transcatheter Tricuspid Valve Replacement System - MarketScreener
Heart valve trial shows 2-year survival edge for Edwards device - Stock Titan
Is Edwards Lifesciences (EW) Pricing Look Attractive After Recent Pullback? - simplywall.st
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report - Barchart.com
Vanguard affiliate reports zero holdings in Edwards Lifesciences (NYSE: EW) - Stock Titan
[DEF 14A] Edwards Lifesciences Corp Definitive Proxy Statement - Stock Titan
EW Stock Price, Quote & Chart | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
SG Americas Securities LLC Grows Stock Position in Edwards Lifesciences Corporation $EW - marketbeat.com
Seilern Investment Management Ltd Has $78.71 Million Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Central Pacific Bank Trust Division Buys New Holdings in Edwards Lifesciences Corporation $EW - Defense World
Is Edwards Lifesciences Corporation (EW) A Good Stock To Buy Now? - Yahoo Finance
Edwards Lifesciences Policy Hire Puts Valuation And Returns In Focus - simplywall.st
AIA Group Ltd Sells 314,688 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
S P Trends: Can Edwards Lifesciences Corporation benefit from deglobalization2026 Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day - MarketWatch
Edwards Beats Heart Valve IP Suit Just Before Trial - Law360
Brevan Howard Capital Management LP Has $3.60 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) Valuation Check After Recent Share Price Momentum - Yahoo Finance
Edwards Lifesciences Stock Hits Day Low of $81.34 Amid Price Pressure - Markets Mojo
Edwards Lifesciences: More Appeal For The Heart (NYSE:EW) - Seeking Alpha
Edwards Lifesciences Corporation $EW Stock Position Lifted by Banco Bilbao Vizcaya Argentaria S.A. - MarketBeat
Edwards Lifesciences Stock (ISIN: US28176E1082) Faces Headwinds Amid Market Cap Dip and Mixed Analys - AD HOC NEWS
EWEdwards Lifesciences Corp Latest Stock News & Market Updates - Stock Titan
Wellington Management Group LLP Buys 977,933 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Chesapeake Capital Corp IL Makes New $1 Million Investment in Edwards Lifesciences Corporation $EW - MarketBeat
Banque Transatlantique SA Has $2.91 Million Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Hits Day High with Strong 3.21% Intraday Surge - Markets Mojo
Edwards Lifesciences (EW) slips 3.3% as investors digest recent conference remarks and insider-selling filings - Quiver Quantitative
Edwards Lifesciences Corp. Experiences Evaluation Revision Amidst Strong Market Performance - Markets Mojo
Van ECK Associates Corp Reduces Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Stock Up 22.1% in a Year: What's Driving It? - Yahoo Finance
Connor Clark & Lunn Investment Management Ltd. Has $42.22 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences Corporation $EW Shares Bought by Bank of Montreal Can - MarketBeat
How The Edwards Lifesciences (EW) Story Is Shifting As 2026 Expectations Tighten - Yahoo Finance
WINTON GROUP Ltd Sells 57,665 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Natixis Advisors LLC Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Acquires New Position in Edwards Lifesciences Corporation $EW - MarketBeat
A Look At Edwards Lifesciences (EW) Valuation As It Exits Critical Care To Focus On Core Heart Therapies - simplywall.st
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences (NYSE: EW) brokered cashless option exercise on 03/11/2026 - Stock Titan
Edwards Lifesciences at Leerink Conference: Strategic Growth and Innovation - Investing.com
Finanzdaten der Edwards Lifesciences Corp-Aktie (EW)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):